COMPTROLLER GENERAL REVIEW OF HEALTH CARE ACTIVITIES OF DEPARTMENT OF DEFENSE RELATING TO GULF WAR ILLNESSES.

SEC. 744. COMPTROLLER GENERAL REVIEW OF HEALTH CARE ACTIVITIES OF DEPARTMENT OF DEFENSE RELATING TO GULF WAR ILLNESSES. (a) Medical Research and Clinical Care Programs.— The Comptroller General shall analyze the effectiveness of the medical research programs and clinical care programs of the Department 110 STAT. 2602of Defense that relate to illnesses that might have been contracted by members of the Armed Forces as a result of service in the Southwest Asia theater of operations during the Persian Gulf War. (b) Policies Regarding Investigational New Drugs.— The Comptroller General shall analyze the scope and effectiveness of the policies of the Department of Defense with respect to— (1) the use of investigational new drugs during the Persian Gulf War to treat members of the Armed Forces who served in the Southwest Asia theater of operations; and (2) the current use of investigational new drugs to treat illnesses referred to in subsection (a). (c) Administration of Medical Records.— The Comptroller General shall analyze the administration of medical records by the military departments in order to assess the extent to which such records accurately reflect the predeployment medical assessments, immunization records, informed consent releases, complaints during routine sick call, emergency room visits, visits with unit medics during deployment, and other relevant medical information relating to the members and former members referred to in subsection (a) with respect to the illnesses referred to in that subsection. (d) Reports.— Not later than March 1, 1997, the Comptroller General shall submit to Congress a separate report on each of the analyses required under subsections (a), (b), and (c).